Press Releases-SINOVAC: Supply Vaccines to Eliminate Human Diseases-page1

2020/12/09

Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine

2020/12/07

Sinovac Reports Unaudited Third Quarter 2020 Financial Results

2020/12/07

Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development

2020/11/11

Brazil's National Health Surveillance Agency Authorizes Resumption of the Phase III Clinical Trial of CoronaVac™

2020/11/10

A Clarification of Interruption in Phase III trial On COVID-19 Vaccine

2020/10/13

A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain

Project Title:A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin StrainProtocol Title:A clinical trial with an open-label phase to evaluate the safety of Sa

2020/09/28

Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

2020/09/23

Sinovac’s Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children

2020/09/22

Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey

2020/09/09

Sinovac Reports Preliminary Phase I/II Results of COVID-19 Vaccine in Elderly Volunteers

2020/08/28

Sinovac Reports Unaudited Second Quarter 2020 Financial Results

2020/08/25

Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation

2020/07/06

Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial

2020/06/30

Sinovac Reports Unaudited First Quarter 2020 Financial Results

2020/06/24

Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine

2020/06/13

Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19

2020/06/11

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

2020/05/22

Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development

2020/05/18

Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital

2020/05/06